KVUE Stock Summary and Trading Ideas (Kenvue | NYSE:KVUE)

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

Kenvue trades on the NYSE stock market under the symbol KVUE.

As of April 24, 2026, KVUE stock price was flat at $17.49 with 6,061,926 million shares trading.

KVUE has a beta of -0.07, meaning it tends to be less sensitive to market movements. KVUE has a correlation of 0.00 to the broad based SPY ETF.

KVUE has a market cap of $33.52 billion. This is considered a Large Cap stock.

Last quarter Kenvue reported $4 billion in Revenue and $.27 earnings per share. This beat revenue expectation by $85 million and exceeded earnings estimates by $.05.

The top ETF exchange traded funds that KVUE belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.

KVUE has underperformed the market in the last year with a price return of -19.5% while the SPY ETF gained +31.9%. KVUE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -0.6% and +0.8%, respectively, while the SPY returned +3.8% and +5.1%, respectively.

KVUE support price is $17.25 and resistance is $17.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KVUE shares will trade within this expected range on the day.